Author correction to ‘Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers’ [Acta Pharmaceutica Sinica B 11 (2021) 355–372]

Tingting Jiang,Guan Wang,Yao Liu,Lu Feng,Meng Wang,Jie Liu,Yi Chen,Liang Ouyang

DOI: https://doi.org/10.1016/j.apsb.2022.02.028

IF: 14.903

2022-03-01

Acta Pharmaceutica Sinica B

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2020.05.004.].

pharmacology & pharmacy

What problem does this paper attempt to address?

Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Wenxing Chen,Yanhong Pan,Siliang Wang,Yuping Liu,Guangying Chen,Liang Zhou,Chao Zhang,Wenting Ni,Aiyun Wang,Yin Lu,Shile Huang

DOI: https://doi.org/10.1186/s12885-019-5458-y

IF: 4.638

2019-01-01

BMC Cancer

Abstract:Following publication of the original article [1], the author noticed the following errors in the article.
Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Xiang P. Liu,Li J. Gao,Ben T. She,Gui X. Li,Yun R. Wu,Ji M. Xu,Zhong J. Ding,Jian F. Ma,Shao J. Zheng

DOI: https://doi.org/10.1111/pce.14419

2022-01-01

Abstract:In the published article, the author names in the byline which originally appeared as “Xiang P. Liu, Li J. Gao, Ben T. She, Gui X. Li, Yun R. Wu, Ji M. Xu, Zhong J. Ding, Jian F. Ma, Shao J. Zheng” have been corrected to “Xiangpei Liu, Lijun Gao, Bentao She, Guixin Li, Yunrong Wu, Jiming Xu, Zhongjie Ding, Jianfeng Ma, Shaojian Zheng” in the byline and the ORCID ID section. We apologize for this error.
Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Hang-Ping Yao,Liang Feng,Sreedhar Reddy Suthe,Ling-Hui Chen,Tian-Hao Weng,Chen-Yu Hu,Eun Sung Jun,Zhi-Gang Wu,Wei-Lin Wang,Song Cheol Kim,Xiang-Min Tong,Ming-Hai Wang

DOI: https://doi.org/10.1186/s40425-019-0571-7

IF: 12.469

2019-01-01

Journal for ImmunoTherapy of Cancer

Abstract:Following publication of the original article [1], the author reported two errors in the authors affiliations:
Author Correction to ‘pharmacologically Targeting Molecular Motor Promotes Mitochondrial Fission for Anti-Cancer’ [acta Pharm Sin B 11 (2021) 1853–1866]

Yi Qian,Meimei Zhao,Qinghua Han,Jingkang Wang,Lixi Liao,Heng Yang,Dan Liu,Pengfei Tu,Hong Liang,Kewu Zeng

DOI: https://doi.org/10.1016/j.apsb.2024.02.013

IF: 14.903

2024-01-01

Acta Pharmaceutica Sinica B

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2021.01.011.].
Erratum: Author correction to 'VEGFR2-targeted antibody fused with IFNamut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity' [Acta Pharm Sin B 11 (2021) 420-433]

Pengzhao Shang,Rui Gao,Yijia Zhu,Xiaorui Zhang,Yang Wang,Minji Guo,Hui Peng,Min Wang,Juan Zhang

DOI: https://doi.org/10.1016/j.apsb.2024.02.014

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2020.09.008.].
Author Correction to “Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy” [acta Pharm Sin B 12 (2022) 4224–4234]

Zekun Li,Yongchun Pan,Shizheng Du,Yayao Li,Chao Chen,Hongxiu Song,Yueyao Wu,Xiaowei Luan,Qiang Xu,Xiaoxiang Guan,Yujun Song,Xin Han

DOI: https://doi.org/10.1016/j.apsb.2023.09.002

IF: 14.903

2024-01-01

Acta Pharmaceutica Sinica B

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2022.06.016.].
Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

Zekun Li,Yongchun Pan,Shiyu Du,Yayao Li,Chao Chen,Hongxiu Song,Yueyao Wu,Xiaowei Luan,Qin Xu,Xiaoxiang Guan,Yujun Song,Xin Han

DOI: https://doi.org/10.1016/j.apsb.2023.09.002

IF: 14.903

2023-01-01

Acta Pharmaceutica Sinica B

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2022.06.016.].
Corrigendum: Multifunctions of CRIF1 in Cancers and Mitochondrial Dysfunction.

Yangzhou Jiang,Yang Xiang,Chuanchuan Lin,Weiwei Zhang,Zhenxing Yang,Lixin Xiang,Yanni Xiao,Li Chen,Qian Ran,Zhongjun Li

DOI: https://doi.org/10.3389/fonc.2023.1271492

IF: 4.7

2023-01-01

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.1009948.].
Author correction to ‘Ablation of Akt2 and AMPKα2 rescues high fat diet-induced obesity and hepatic steatosis through Parkin-mediated mitophagy’ [Acta Pharmaceutica Sinica B 11 (2021) 3508–3526]

Shuyi Wang,Jun Tao,Huaguo Chen,Machender R. Kandadi,Mingming Sun,Haixia Xu,Gary D. Lopaschuk,Yan Lu,Junmeng Zheng,Hu Peng,Jun Ren

DOI: https://doi.org/10.1016/j.apsb.2022.12.015

IF: 14.903

2023-01-01

Acta Pharmaceutica Sinica B

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2021.07.006.].
Correction: A Novel Highly Potent Trivalent TGF-β Receptor Trap Inhibits Early-Stage Tumorigenesis and Tumor Cell Invasion in Murine Pten-deficient Prostate Glands

Tai Qin,Lindsey Barron,Lu Xia,Haojie Huang,Maria M. Villarreal,John Zwaagstra,Cathy Collins,Junhua Yang,Christian Zwieb,Ravindra Kodali,Cynthia S. Hinck,Sun Kyung Kim,Robert L. Reddick,Chang Shu,Maureen D. O'Connor-McCourt,Andrew P. Hinck,Lu-Zhe Sun

DOI: https://doi.org/10.18632/oncotarget.13343

2016-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.13343.].
Erratum: Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics [Corrigendum]

DOI: https://doi.org/10.2147/IJN.S500182

2024-10-14

Abstract:[This corrects the article DOI: 10.2147/IJN.S448556.].
Erratum: Author correction to '3- O-Acetyl-11-keto- β-boswellic acid ameliorated aberrant metabolic landscape and inhibited autophagy in glioblastoma' [Acta Pharm Sin B 10 (2020) 301-312]

Wan Li,Liwen Ren,Xiangjin Zheng,Jinyi Liu,Jinhua Wang,Tengfei Ji,Guanhua Du

DOI: https://doi.org/10.1016/j.apsb.2024.04.025

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2019.12.012.].
Corrigendum to"Synergistically targeting synovium STING pathway for rheumatoid arthritis treatment" [Bioact Mater 24 (2022) 37-53]

Haotian Shen,Lulu Jin,Qiangqiang Zheng,Ziqiang Ye,Linxiang Cheng,Yuxu Wu,Honghao Wu,Tae Gyong Jon,Wenduo Liu,Zongyou Pan,Zhengwei Mao,Yue Wang

DOI: https://doi.org/10.1016/j.bioactmat.2024.08.007

2024-08-22

Abstract:[This corrects the article DOI: 10.1016/j.bioactmat.2022.12.001.].
Corrigendum to “TREAT: Therapeutic RNAs exploration inspired by artificial intelligence technology” [Comput Struct Biotechnol J 20 (2022) 5680–5689]

Yufan Luo,Liu Liu,Zihao He,Shanshan Zhang,Peipei Huo,Zhihao Wang,Qin Jiaxin,Lianhe Zhao,Yang Wu,Dongdong Zhang,Dechao Bu,Runsheng Chen,Yi Zhao

DOI: https://doi.org/10.1016/j.csbj.2023.05.018

IF: 6.155

2023-01-01

Computational and Structural Biotechnology Journal

Abstract:[This corrects the article DOI: 10.1016/j.scr.2023.103115.].

biochemistry & molecular biology
Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer (Nature Nanotechnology, (2019), 14, 4, (388-397), 10.1038/s41565-019-0381-6)

Jiangsheng Xu,Yunhua Liu,Yujing Li,Hai Wang,Samantha Stewart,Kevin Van der Jeught,Pranay Agarwal,Yuntian Zhang,Sheng Liu,Gang Zhao,Jun Wan,Xiongbin Lu,Xiaoming He

DOI: https://doi.org/10.1038/S41565-019-0417-Y

IF: 38.3

2019-01-01

Nature Nanotechnology

Abstract:The Supplementary Information originally published with this Article was an older version, in which ‘IFN-γ’ was misspelled ‘INF-γ’ in Supplementary Fig. 9 and the β-Actin blot in Supplementary Fig. 13 was the wrong image. The Supplementary Information has now been replaced.
Correction: Lertsuwan et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers 2018, 10, 283

Jomnarong Lertsuwan,Kornkamon Lertsuwan,Anyaporn Sawasdichai,Nathapol Tasnawijitwong,Ka Ying Lee,Philip Kitchen,Simon Afford,Kevin Gaston,Padma-Sheela Jayaraman,Jutamaad Satayavivad

DOI: https://doi.org/10.3390/cancers15010133

2022-12-26

Abstract:Authors would like to make a correction to the previous article [...].
Correction: Tumor Driven by Gain-of-function HER2 H878Y Mutant is Highly Sensitive to HER2 Inhibitor.

Zexi Hu,Yong Hu,Xicheng Liu,Rongwen Xi,Aiqun Zhang,Deruo Liu,Qiang Xie,Liang Chen

DOI: https://doi.org/10.18632/oncotarget.26252

2018-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.5221.].
Correction: Radiopharmaceutical-activated silicon naphthalocyanine nanoparticles towards tumor photodynamic therapy

Tingting Wang,Jingchao Li,Xun Zhang,Chengao Li,Jiang Ming,Jian Li,Dongsheng Zhang,Jun Yang,Nian Liu,Xinhui Su

DOI: https://doi.org/10.1039/d4cc90284j

2024-08-29

Abstract:Correction for 'Radiopharmaceutical-activated silicon naphthalocyanine nanoparticles towards tumor photodynamic therapy' by Tingting Wang et al., Chem. Commun., 2024, https://doi.org/10.1039/d4cc03281k.
Corrigendum: Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer

Xin Tian,Lina Wu,Min Jiang,Zhenyong Zhang,Rong Wu,Jianing Miao,Caigang Liu,Song Gao

DOI: https://doi.org/10.3389/fonc.2022.793448

IF: 4.7

2022-04-06

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.641399.].

oncology
Corrigendum: An in vivo fluorescence resonance energy transfer-based imaging platform for targeted drug discovery and cancer therapy

Fuqiang Xing,Nana Ai,Shigao Huang,Cheng Jiang,Muhammad Jameel Mughal,Wei Ge,Guanyu Wang,Chu-Xia Deng

DOI: https://doi.org/10.3389/fbioe.2022.1039177

IF: 5.7

2022-09-26

Frontiers in Bioengineering and Biotechnology

Abstract:[This corrects the article DOI: 10.3389/fbioe.2022.839078.].

multidisciplinary sciences

Author correction to ‘Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers’ [Acta Pharmaceutica Sinica B 11 (2021) 355–372]

Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Author Correction to ‘pharmacologically Targeting Molecular Motor Promotes Mitochondrial Fission for Anti-Cancer’ [acta Pharm Sin B 11 (2021) 1853–1866]

Erratum: Author correction to 'VEGFR2-targeted antibody fused with IFNamut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity' [Acta Pharm Sin B 11 (2021) 420-433]

Author Correction to “Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy” [acta Pharm Sin B 12 (2022) 4224–4234]

Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

Corrigendum: Multifunctions of CRIF1 in Cancers and Mitochondrial Dysfunction.

Author correction to ‘Ablation of Akt2 and AMPKα2 rescues high fat diet-induced obesity and hepatic steatosis through Parkin-mediated mitophagy’ [Acta Pharmaceutica Sinica B 11 (2021) 3508–3526]

Correction: A Novel Highly Potent Trivalent TGF-β Receptor Trap Inhibits Early-Stage Tumorigenesis and Tumor Cell Invasion in Murine Pten-deficient Prostate Glands

Erratum: Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics [Corrigendum]

Erratum: Author correction to '3- O-Acetyl-11-keto- β-boswellic acid ameliorated aberrant metabolic landscape and inhibited autophagy in glioblastoma' [Acta Pharm Sin B 10 (2020) 301-312]

Corrigendum to"Synergistically targeting synovium STING pathway for rheumatoid arthritis treatment" [Bioact Mater 24 (2022) 37-53]

Corrigendum to “TREAT: Therapeutic RNAs exploration inspired by artificial intelligence technology” [Comput Struct Biotechnol J 20 (2022) 5680–5689]

Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer (Nature Nanotechnology, (2019), 14, 4, (388-397), 10.1038/s41565-019-0381-6)

Correction: Lertsuwan et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers 2018, 10, 283

Correction: Tumor Driven by Gain-of-function HER2 H878Y Mutant is Highly Sensitive to HER2 Inhibitor.

Correction: Radiopharmaceutical-activated silicon naphthalocyanine nanoparticles towards tumor photodynamic therapy

Corrigendum: Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer

Corrigendum: An in vivo fluorescence resonance energy transfer-based imaging platform for targeted drug discovery and cancer therapy